An analysis of nearly 50 randomized controlled trials has found no link between treatment with glucagon-like peptide (GLP)-1 receptor agonists, either for type 2 diabetes or weight management, and cancer risk.

The findings may serve as “a very important piece of information for clinicians,” said the study’s senior author Cho-Han Chiang, MD, MMSc, from Harvard Medical School.

He explained that initial safety reports suggested there might be an increased risk for thyroid and pancreatic cancer with GLP-1 receptor agonist use.

“Notably, in our meta-analysis we did not show such a signal across the broad spectrum of GLP-1 receptor agonists,” Chiang told Inside Precision Medicine .

Chiang and colleagues also found no link between the treatments, which are increasingly used for glycemic con

See Full Page